Keros Therapeutics Inc (KROS)
53.99
-0.41
(-0.75%)
USD |
NASDAQ |
May 16, 16:00
54.02
+0.04
(+0.06%)
After-Hours: 20:00
Keros Therapeutics Cash from Operations (TTM): -134.83M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -134.83M |
| December 31, 2023 | -124.51M |
| September 30, 2023 | -120.49M |
| June 30, 2023 | -111.11M |
| March 31, 2023 | -102.87M |
| December 31, 2022 | -70.06M |
| September 30, 2022 | -68.18M |
| June 30, 2022 | -58.02M |
| March 31, 2022 | -53.07M |
| Date | Value |
|---|---|
| December 31, 2021 | -62.15M |
| September 30, 2021 | -50.57M |
| June 30, 2021 | -46.99M |
| March 31, 2021 | -39.28M |
| December 31, 2020 | -36.89M |
| September 30, 2020 | -34.40M |
| June 30, 2020 | -26.50M |
| March 31, 2020 | -21.60M |
| December 31, 2019 | -16.00M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-134.83M
Minimum
Mar 2024
-16.00M
Maximum
Dec 2019
-65.42M
Average
-55.55M
Median
Cash from Operations (TTM) Benchmarks
| Morphic Holding Inc | -127.25M |
| NovaBay Pharmaceuticals Inc | -4.516M |
| Palatin Technologies Inc | -26.54M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -18.27M |